ClinicalTrials.gg
RecruitingNCT07641426Updated Jul 22, 2026

A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).

A Phase 1/2 interventional study of CID-103 in Antibody Mediated Rejection, sponsored by CASI pharmaceuticals, Inc.. Recruiting at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by CASI pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
58
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with with active and chronic active renal allograft antibody mediated rejection (ABMR). The main questions the study aims to answer are:• To evaluate the safety and tolerability of CID-103 in subjects with ABMR with different increasing doses of CID-103.• To evaluate clinical efficacy of CID-103 at an optimal dose in participants with active and chronic active ABMR following renal allograft transplant. The study will be done in two parts: Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range. Part B will enroll approximately 40 participants to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 12 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness. This study is an important step toward developing a new treatment for people living with ABMR. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.

02

Conditions studied

  • Antibody Mediated Rejection
03

In context

Lead sponsor

This is the only study on the registry with CASI pharmaceuticals, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years old at time of signing of ICF.
  2. Voluntary, written, prior to study-specific procedures.
  3. Functioning living or deceased donor renal allograft ≥ 180 days post-transplant.
  4. ≥ 25 mL/min/1.73 m2 chronic kidney disease epidemiology collaboration (CKD-EPI 2021, see APPENDIX A).
  5. HLA class I and/or II antigen-specific antibodies (preformed and/or dnDSA).
  6. Existing diagnosis of active or chronic/active ABMR (± C4d in peritubular capillaries) within the last 180 days according to the Banff 2022 classification as per local pathology read.
  7. Must have a renal within 28 days (preferably within 14 days) of first study drug administration for central pathology review. Results of the central pathology review are not required prior to first study drug administration.
  8. Participants who have been diagnosed with pre-existing HLA class I/II DSA at the time of their original renal allograft transplant must have received prior treatment with intravenous immune globulin (IVIG) and plasmapheresis (unless ).
  9. Participants with active ABMR may have received prior treatment with IVIG and plasmapheresis (not required).
  10. For participants that have received prior IVIG, subcutaneous immunoglobulin (SCIg), plasmapheresis, complement system inhibitors (e.g., eculizumab), proteasome inhibitors (e.g., bortezomib) or an interleukin-6 inhibitor (e.g. tocilizumab), or an anti-CD20 (e.g., rituximab) a ≥12 weeks is required prior to first study drug administration
  11. Standardized immune suppression regimen.
  12. Adequate organ function without transfusions, within 14 days of first dose of study drug.
  13. .

Exclusion criteria

Exclusion Criteria:

  1. ABO-incompatible transplant.
  2. Any of the following on baseline :

    1. T-cell-mediated rejection classified Banff Grade ≥ 1.
    2. de novo or recurrent severe thrombotic microangiopathy.
    3. polyoma virus nephropathy.
    4. de novo or recurrent glomerulonephritis.
  3. Acute rejection treatment within 180 days of dosing.
  4. to repeat biopsies.
  5. Previous treatment with other anti-CD38 monoclonal antibodies.
  6. Other immunomodulatory antibodies within ≤ 90 days of dosing.
  7. Receiving other concurrent therapies or have received investigational therapies within four weeks of the first dose of study drug or five half-lives (if shorter).
  8. Participants unable to modify baseline immune suppression.
  9. Active viral, bacterial, or fungal infection precluding intensified .
  10. Known latent or active tuberculosis.
  11. Known active infection with (HIV).
  12. Known active infection.
  13. IgG \< 400 mg/dL.
  14. Other chronic or acute disease(s) likely to interfere with study endpoint evaluation.
  15. Active malignant disease or premalignant condition within two years, precluding intensified immunosuppressive therapy.
  16. Administration of a ≤ 6 weeks of screening.
  17. Participation in interventional component of another clinical trial.
  18. History or clinical evidence of any surgical or medical condition which the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, particularly any pre-existing condition that would put the participant at additional risk should they experience an IRR.
  19. Any unresolved treatment-related AE(s) from prior treatment that have not resolved to Grade 1 or baseline value prior to first dose of study drug.
  20. Known to CID-103 or prior severe hypersensitivity to a monoclonal antibody.
  21. Participants who experienced a Grade 3 or 4 AE related to prior administration of monoclonal antibodies, which the Investigator feels may recur and/or put the participant at significant risk, should be excluded.
  22. Previous Grade 4 anaphylactic reaction to other therapeutic proteins.
  23. Chronic dependence on transfusions or hematopoietic growth factors to maintain acceptable blood counts excluding those participants who require ESAs for documented erythropoietin deficiency. Participants cannot have had a transfusion within the past 14 days prior to first dose of study drug or have had more than 1 transfusion in the past month.
  24. Inability to perform study baseline red blood cell (RBC) type and crossmatch, phenotype (and genotype, if applicable) or lack of available baseline data on RBC phenotype (or genotype, if applicable).
  25. Unable or not willing to agree to the evaluation of RBC antigens by phenotyping or genotyping.
  26. Unable or not willing to comply with the protocol and the visit schedule restrictions and assessments therein.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Part A (Dose Escalation) Cohort 1- 150 mg/300 mg

    This is the initial dose cohort with accelerated dose escalation design. If ≥ 1 out of the 3 participants in the cohort experience a related Grade ≥3 AE or study-specific safety event, the cohort will expand to 6 participants.

    Drug: CID-103

  • Experimental
    Part A (Dose Escalation) Cohort 2- 150 mg/600 mg

    This is the second dose cohort with accelerated dose escalation design. If ≥ 1 out of the 3 participants in the cohort experience a related Grade ≥3 AE or study-specific safety event, the cohort will expand to 6 participants.

    Drug: CID-103

  • Experimental
    Part A (Dose Escalation) Cohort 3- 150 mg/900 mg

    This is the third dose cohort with accelerated dose escalation design. If ≥ 1 out of the 3 participants in the cohort experience a related Grade ≥3 AE or study-specific safety event, the cohort will expand to 6 participants.

    Drug: CID-103

  • Experimental
    Part B cohort- 150 mg/dose selected from Part A

    Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at their target dose administered.

    Drug: CID-103

Interventions

  • Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at the higher target dose administered for up to a maximum treatment duration of 49 weeks, in the absence of treatment failure or stopping criteria.

06

What researchers measure

Primary outcomes

  1. Arms A: Number of participants experiencing study-specific safety events or meeting treatment stopping criteria

    Time frame: Up to Week 65

  2. Arms A: Number of participants with AEs with focus on infections, cytopenias, and IRRs

    Time frame: Up to Week 65

  3. Arms A: Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to Week 65

  4. Arms A: Number of Participants With Anti-Drug Antibody (ADA)

    Time frame: Up to week 65

  5. Part B: Number of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 24

    Time frame: at Week 24

Secondary outcomes

  1. Part A: Number of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 24 and Week 52

    Time frame: at Week 24 and Week 52

  2. Part B: Number of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 52

    Time frame: Week 52

  3. Arms A and B: Number of Participants with Changes From Baseline in Any Clinically Significant Laboratory Abnormalities

    Time frame: up to Week 65

  4. Arms A and B: Change From Baseline in Urine Protein Creatinine Ratio (UPCR)

    Time frame: Up to Week 65

  5. Part A and B: Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Up to Week 65

  6. Arms A and B: Change From Baseline in Urine Protein

    Time frame: Up to Week 65

  7. Arms B: Number of participants with AEs with focus on infections, cytopenias, and IRRs

    Time frame: Up to Week 65

  8. Arms B: Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to Week 65

  9. Arms A and B: Change From Baseline in Donor-Specific-Antibodies (DSA)

    Time frame: Up to Week 65

  10. Arms A and B: Change From Baseline in Donor-Derived Cell-Free DNA (dd-cfDNA)

    Time frame: up to week 65

  11. Part A and B: Number of Participants With All-cause Allograft Failure After Treatment of CID-103

    Time frame: Up to Week 65

  12. Part A and B: Percentage of Participants Survival Rate at Week 65

    Time frame: Up to Week 65

  13. Parts A and B: CID-103 Serum Concentrations

    Time frame: Up to Week 65

07

Study locations

1 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2030, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 11, 2026
StartActual
Jun 9, 2026
Primary completionEst.
May 2030
CompletionEst.
Dec 2030
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07641426
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Jun 9, 2026
Primary completion
May 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jul 22, 2026

Study contacts

Junping Chen
Contact
junpingc@casipharmaceuticals.com
202-617-6071
Junping Chen
study chair · CASI pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CID-103

Start the discussion